medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2014, Número 2

<< Anterior

Residente 2014; 9 (2)


Células troncales mesenquimales: potencial de terapia celular en trasplante de células troncales hematopoyéticas

Castro-Manrreza ME, Montesinos JJ

Idioma: Español
Referencias bibliográficas: 30
Paginas: 66-73
Archivo PDF: 309.58 Kb.


RESUMEN

A través del desarrollo de los mamíferos se generan diferentes tipos de células troncales. Cada una de ellas se caracteriza por poseer cierto potencial de diferenciación, siendo el cigoto el de mayor potencial. Una vez formados los tejidos, prácticamente en cada uno de ellos se localizan células troncales somáticas, las cuales tienen un potencial de diferenciación restringido. Ejemplo de ellas son las células troncales mesenquimales, las cuales se localizan en la médula ósea, y debido a sus características biológicas, es prometedor su uso en protocolos de terapia celular. En particular, estas células tienen capacidad de soporte hematopoyético y propiedades inmunosupresoras, y debido a ello, se han empleado para mejorar el trasplante de células troncales hematopoyéticas y el tratamiento de la enfermedad injerto contra hospedero.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lemoli RM, Bertolini F, Cancedda R, De Luca M, Del Santo A, Ferrari G et al. Stem cell plasticity: time for a reappraisal? Haematologica. 2005; 90: 360-381.

  2. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood. 2003; 15: 3483-3493.

  3. Watt FM, Driskell RR. The therapeutic potential of stem cells. Philos Trans R Soc Lond B Biol Sci. 2010; 12: 155-163.

  4. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010; 28: 585-596.

  5. Montesinos JJ, Castro ME. Células troncales mesenquimales. En: Pelayo R, Santana-Olalla J, Velasco I, eds. Células troncales y medicina regenerativa. México: Buena Onda; 2011. pp. 119-138.

  6. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006; 20 (3): 161-171.

  7. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974; 2: 83-92.

  8. Zhang Y, Adachi Y, Suzuki Y et al. Simultaneous injection of bone marrow cells and stromal cells into bone marrow accelerates hematopoiesis in vivo. Stem Cells. 2004; 22: 1256-1262.

  9. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet. 2004; 363: 1439-1441.

  10. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potencial clinical uses. Exp Hematol. 2000; 28: 875-884.

  11. Wagner W, Roderburg C, Wein F et al. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells. 2007; 25: 2638-2647.

  12. Gottschling S, Saffrich R, Seckinger A, Krause U, Horsch K, Miesala K et al. Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism. Stem Cells. 2007; 25 (3): 798-806.

  13. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-versus-host disease: pathobiology and management. Exp Hematol. 2001; 29: 259-277.

  14. Rezvani AR, Storb RF. Separation of graft-versus-tumor effects from graft-versus-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun. 2008; 30: 172-179.

  15. Martin PJ. Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. Keio J Med. 2008; 57: 177-183.

  16. Reddy P, Arora M, Guimond M, Mackall CL. GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant. 2009; 15: 162-168.

  17. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 2: 1550-1561.

  18. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005; 105: 4120-4126.

  19. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005; 105: 2214-2219.

  20. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004; 103: 4619-4621.

  21. Maccario R, Podestá M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005; 90: 516-525.

  22. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105: 1815-1822.

  23. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006; 24: 386-398.

  24. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007; 92: 881-888.

  25. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role ofindoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008; 111: 1327-1333.

  26. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390-1397.

  27. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2013 Dec 6 [Epub ahead of print].

  28. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013; 19: 225-238.

  29. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013; 98: 206-213.

  30. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013; 163: 501-509.




2020     |     www.medigraphic.com